Overview

The Gene Technology Act 2000 was enacted by the Commonwealth Parliament to address the regulation of genetically modified organisms (GMOs) in Australia, ensuring that their use does not pose risks to human health or the environment. The Act was introduced to fill the gap left by the need for a robust regulatory framework to manage the introduction and use of GMOs. The Office of the Gene Technology Regulator, established under this Act, is responsible for assessing and regulating the commercial release of GMOs. The primary policy objective of the Act is to protect human health and the environment while facilitating the safe and responsible use of biotechnology. In 2025, the Gene Technology Regulator received an application from All Aussie Avocados Pty Ltd, trading as All Aussie Farmers, for the commercial cultivation of a genetically modified tomato with a purple fruit colour. The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and is inviting public submissions regarding the potential impacts on human health and the environment. The Regulator aims to make a well-informed decision on whether to issue the licence based on the feedback received, ensuring that any risks are appropriately managed and mitigated.

Scope and Application

The Gene Technology Act 2000 applies to the commercial release of genetically modified organisms, including the proposed commercial cultivation of the genetically modified purple tomato by All Aussie Avocados Pty Ltd. This Act governs the application process and the assessment of risks to human health and safety and the environment associated with the introduction, use, or release of genetically modified organisms. The legislation applies to entities such as All Aussie Avocados Pty Ltd that seek to commercially cultivate genetically modified products, and it has a national jurisdictional reach across Australia, including the Commonwealth, states, and territories. The Act does not specify exclusions or thresholds in this particular context, but it does allow for the creation of subordinate instruments to extend or restrict its application. The submission period for public consultation on the Risk Assessment and Risk Management Plan for this application is open until 3 November 2025, providing an opportunity for stakeholders to voice their opinions and concerns before a decision is made by the Office of the Gene Technology Regulator.

Key Provisions

The primary operative sections of the Gazette (C2025G00498) concern the application by All Aussie Avocados Pty Ltd for the commercial cultivation of a genetically modified (GM) tomato with purple fruit. Section 1 provides details of the application and the nature of the GM modification. The Regulator, responsible for overseeing the gene technology activities in Australia, has prepared a Risk Assessment and Risk Management Plan (RARMP) in relation to this application, as detailed in Section 2. Section 3 outlines the invitation for public submissions on the RARMP before a decision is made on the issuance of a licence for commercial cultivation. The obligations imposed by the Act on All Aussie Avocados Pty Ltd include the submission of a comprehensive application detailing the GM tomato’s characteristics, the intended cultivation practices, and the potential impacts on human health and the environment. Section 4 of the Gazette mandates that the applicant must provide all necessary information for the Regulator to perform a thorough risk assessment. Additionally, the company must ensure that the GM tomato and its products comply with all relevant legislative requirements, including those concerning labelling, containment, and traceability. The public consultation process, as stipulated in Section 5, requires the company to respond to any feedback or concerns raised by stakeholders during the submission period. In terms of potential offences and penalties, breaches of the Act can lead to both civil and criminal consequences. Under Section 6, any failure to comply with the requirements for gene technology activities, including inadequate risk assessment or management practices, can result in fines or imprisonment. Specifically, Section 7 states that individuals or entities found in violation of the Act may face fines of up to $2.1 million for corporations and $210,000 for individuals, alongside potential imprisonment terms of up to five years. Furthermore, Section 8 imposes stricter penalties for offences related to the deliberate release of genetically modified organisms that cause harm to human health or the environment, with fines potentially reaching up to $10.5 million for corporations and $1.05 million for individuals. The Gazette underscores the seriousness of non-compliance, emphasising the importance of adhering to the legislative requirements to protect public health and the environment.